Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal

The timing of these two departures could be coincidental and mean nothing, or they might signal Sanofi's interest in acquiring Sarepta.

Alexion Rises More Than 5% After Beating Consensus

Alexion Rises More Than 5% After Beating Consensus

Soliris sales of $783 million in the first quarter benefited from a one-time, $29 million change in revenue recognition but still came in higher than consensus.

Acorda Shares Fall 5% in an Earnings Miss

Acorda Shares Fall 5% in an Earnings Miss

Net revenue for its Ampyra totaled $112 million, short of the $121 million consensus.

Biomarin Newly Approved Drug for Rare, Childhood Disease Will Cost $700K Per Year

Biomarin Newly Approved Drug for Rare, Childhood Disease Will Cost $700K Per Year

Brineura is first and only treatment for CLN2 disease, a form of Batten disease.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.